Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.75 |
| ▸ | CHUK | O15111 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381722 | 0.89 | IKBKB (0.76) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4975571 | 0.86 | IKBKB (0.62) | IKBKBPTPN1MEN1KMT2AKDM4E | |
| SCHEMBL5898645 | 0.81 | IKBKB (0.80) | IKBKBMEN1JAK2EIF2AK2KMT2A | |
| SCHEMBL4975594 | 0.80 | IKBKB (0.52) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3618767 | 0.80 | IKBKB (0.61) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7054758 | 0.78 | KDM4E (0.70) | IKBKBPTPN1MEN1KMT2AKDM4E | |
| SCHEMBL4091841 | 0.76 | IKBKB (1.00) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4086105 | 0.75 | IKBKB (0.78) | IKBKBCYP1A2CYP3A4CYP2C9PTPN1 | |
| SCHEMBL2157899 | 0.75 | NPSR1 (0.81) | IKBKBCHUKCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1385004 | 0.75 | IKBKB (1.00) | IKBKBPTPN1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448545-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | claimed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | claimed |
| EP-1448545-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040192943-A1 | Nf-kappab inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1448545-A1 | NF-KB INHIBITORS | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003029242-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1448545-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1448545-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192943-A1 | Nf-kappab inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1448545-A1 | NF-KB INHIBITORS | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003029242-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192943-A1 | Nf-kappab inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885CHUK 8/4885CYP1A2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.